Biomea Fusion
BMEA · Nasdaq · United States
Share price · BMEA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BMEA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Oct 2026-15.2%
Nothing announced by BMEA that day or the session before.
- 20 Oct 2026-12.0%
Nothing announced by BMEA that day or the session before.
- 14 Oct 2026-33.8%
- 25 Sep 2026-11.4%
Nothing announced by BMEA that day or the session before.
- 23 Sep 2026-15.3%
- 24 Aug 2026+16.1%
- 17 Apr 2026+14.5%
Nothing announced by BMEA that day or the session before.
- 7 Apr 2026+25.8%
Nothing announced by BMEA that day or the session before.
- 26 Mar 2026+12.3%
Nothing announced by BMEA that day or the session before.
- 16 Mar 2026-8.1%
Nothing announced by BMEA that day or the session before.
Share of unusual movement by asset
For each asset, the share of BMEA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | MeninSmall molecule | Type 2 DiabetesType 1 Diabetes | |
| Phase 1 | GLP-1 receptorSmall molecule | Obesity |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (20)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $8.5M | $27M | $6.2M-$8.4M operating cash flow | report ↗ |
View 19 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $9.1M | $35M | $8.3M-$10M operating cash flow | report ↗ |
| 2026-Q1 | — | $9.1M | $45M | $12M-$12M operating cash flow | report ↗ |
| 2025-Q3 | — | $14M | $47M | $16M-$12M operating cash flow | report ↗ |
| 2025-Q2 | — | $17M | $57M | $21M-$19M operating cash flow | report ↗ |
| 2025-Q1 | — | $23M | $36M | $29M-$26M operating cash flow | report ↗ |
| 2024-Q4 | — | $25M | $59M | $29M-$30M operating cash flow | report ↗ |
| 2024-Q3 | — | $27M | $88M | $33M-$25M operating cash flow | report ↗ |
| 2024-Q2 | — | $32M | $114M | $37M-$33M operating cash flow | report ↗ |
| 2024-Q1 | — | $34M | $145M | $39M-$32M operating cash flow | report ↗ |
| 2023-Q4 | — | $31M | $177M | $35M-$23M operating cash flow | report ↗ |
| 2023-Q3 | — | $25M | $199M | $28M-$24M operating cash flow | report ↗ |
| 2023-Q2 | — | $22M | $223M | $25M-$26M operating cash flow | report ↗ |
| 2023-Q1 | — | $24M | $87M | $29M-$24M operating cash flow | report ↗ |
| 2022-Q4 | — | $21M | $112M+ $1.1M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $18M | $133M+ $1.1M short-term inv. | $23M-$17M operating cash flow | report ↗ |
| 2022-Q2 | — | $13M | $149M+ $1.1M short-term inv. | $17M-$15M operating cash flow | report ↗ |
| 2022-Q1 | $1.1B | $11M | $157M+ $8.6M short-term inv. | $16M-$10.0M operating cash flow | report ↗ |
| 2021-Q4 | — | $11M | $146M+ $28M short-term inv. | $15M-$16M operating cash flow | report ↗ |
| 2021-Q3 | — | $7.9M | $157M+ $32M short-term inv. | $13M-$9.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $62M | $56M | $15M-$70M operating cash flow | report ↗ |
Biomea Fusion reported full-year 2025 results with revenue not disclosed. R&D expenses were $61.98M, down 47.5% YoY from $118.09M, while cash, cash equivalents, and restricted cash totaled $56.18M. The company reported a net loss of $61.8M for the year.
The company projected a cash runway into the first quarter of 2027. Clinical highlights include initiation of Phase II trials COVALENT-211 and COVALENT-212 for icovamenib in type 2 diabetes, with 26-week primary endpoint data expected in the fourth quarter of 2026, and completion of the 52-week follow-up from Phase II COVALENT-112 in type 1 diabetes, with data expected in the second quarter of 2026. Enrollment also began for the Phase I GLP-131 trial of BMF-650 in obesity, with initial 28-day weight reduction data anticipated in the second quarter of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $118M | $59M | $35M-$120M operating cash flow | report ↗ |
| 2023-FY | — | $103M | $177M | $29M-$97M operating cash flow | report ↗ |
| 2022-FY | — | $63M | $112M+ $1.1M short-term inv. | $20M-$62M operating cash flow | report ↗ |
| 2021-FY | — | $28M | $146M+ $28M short-term inv. | $10M-$35M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($197K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-10 | Averill Julianne · director | Award / grant (derivative) | 173,711 | — | — | Form 4 |
| 2026-06-10 | Ray Sumita · director | Award / grant (derivative) | 196,299 | — | — | Form 4 |
| 2026-06-10 | AGUIAR ERIC · director | Award / grant (derivative) | 196,299 | — | — | Form 4 |
| 2026-06-10 | Faust Elizabeth · director | Award / grant (derivative) | 196,299 | — | — | Form 4 |
| 2026-04-01 | Hitchcock Michael J.M. · director, Interim CEO | Award / grant (derivative) | 667,477 | — | — | Form 4 |
| 2026-04-01 | Erdtmann Rainer M · director, See Remarks | Award / grant (derivative) | 452,512 | — | — | Form 4 |
| 2025-12-11 | Erdtmann Rainer M · director, See Remarks | Open-market purchase | 30,000 | $1.43 | $43K | Form 4 |
| 2025-12-02 | Hitchcock Michael J.M. · director, Interim CEO | Open-market purchase | 100,000 | $0.99 | $99K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 64 reporting institutions held 24.3M shares ($37.1M, 33.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 8,813,359 | $13.5M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,597,300 | $4.0M |
| 3 | Aisling Capital Management LP | 2,048,757 | $3.1M |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,312,798 | $2.0M |
| 5 | MARSHALL WACE, LLP | 1,198,551 | $1.8M |
| 6 | CITADEL ADVISORS LLC | 656,817 | $1.0M |
| 7 | Mariner, LLC | 654,578 | $1.0M |
| 8 | BlackRock, Inc. | 641,435 | $981K |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 629,865 | $964K |
| 10 | FIDEURAM - INTESA SANPAOLO PRIVATE BANKING S.P.A. | 557,036 | $852K |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 548,186 | $839K |
| 12 | XTX Topco Ltd | 530,542 | $812K |
| 13 | UBS Group AG | 515,555 | $789K |
| 14 | TWO SIGMA INVESTMENTS, LP | 388,696 | $595K |
| 15 | MORGAN STANLEY | 346,742 | $531K |